FDA has approved Tibsovo (ivosidenib) for adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as detected by an FDA-approved test.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
